NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR INTO ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

Hansa Biopharma announces intention to carry out a placing of new ordinary shares

The capital injection will enable Hansa Biopharma to fund its R&D efforts, incl. advancing its three phase 2 programs and development of the next generation enzymes for repeat dosing. In addition the Company intends to fund the commercial build-up in Europe.

Lund, Sweden July 8, 2020. Hansa Biopharma, ("Hansa") the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its intention to issue up to approximately 4.4 million new ordinary shares through an accelerated bookbuild placing to institutional investors (the "Placing").

The Placing is being conducted through an accelerated book building process, which will commence immediately following this announcement and may close at any time. The offer price will be determined after the close of the accelerated book-building process. Once the Placing is completed the Board of Directors of Hansa Biopharma intends to resolve upon a directed share issue pursuant to the authorisation granted by the Annual General Meeting held on June 23, 2020.

A further announcement will be made following the completion of the Placing. In conjunction with the Placing, the Company has engaged Morgan Stanley & Co. International plc and Kempen & Co as joint bookrunners and Zonda Partners AB as co-manager, as well as Advokatfirman Vinge as legal adviser. White & Case acts as legal adviser to the banks in connection with the Placing.

The net proceeds of the Placing will be used to continue the development and expansion of the Company's R&D pipeline as well as to fund the potential launch and commercialization of imlifidase in kidney transplantation. More specifically, the proceeds will enable the Company to:

- Fund the Company's ongoing and future R&D efforts, including development of imlifidase for additional indications such as antibody-mediated kidney transplant rejection (AMR), Guillain-Barré syndrome (GBS) and anti-GBM disease (GBM);
- Fund Hansa Biopharma's ongoing commercial build-up, including expanding the sales force, in preparation for the potential launch of imlifidase in kidney transplantation in highly sensitized patients in Europe;
- Continue to invest in the Company's development of next generation IgG-eliminating enzymes for repeat dosing; and
- Fund working capital and general corporate purposes

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

The information was submitted for publication, through the contact person set out below, at 5:31pm (CET) on July 8, 2020.

Contact information
Klaus Sindahl
Head of Investor Relations
Hansa Biopharma
M: +46 (0) 709–298 269
E: klaus.sindahl@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company's lead product candidate, imlifidase, is an antibodycleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications.

CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020.

Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.

Hansa Biopharma
Scheelevägen 22
SE- 223 63 Lund, Sweden
Phone: +46 46 16 56 70
www.hansabiopharma.com

Nasdaq OMX Stockholm
Ticker: HNSA
ISIN: SE 0002148817

The reasons for the deviation from the shareholders' pre-emption rights are to secure a capital raise in a timely and cost-efficient manner, as well as to strengthen the shareholder base of the Company.

Subject to customary exceptions, the Company and the management and board members of the Company have agreed to undertake a lock-up commitment for 90 calendar days following settlement of the Placing.

First half 2020– Key financials

Due to the contemplated directed issue Hansa Biopharma hereby chooses to provide an update on certain financial information for the period January 1 – June 30, 2020, with comparative figures for the corresponding period in 2019. The figures are preliminary and unaudited and have been retrieved from the Company's management accounts. The final figures are expected to be presented in the Company's interim report for the period ending June 30, 2020, which are scheduled to be published on July 16, 2020.

In MSEK; Unaudited, H1 2020 preliminary	H1 2020	H1 2019
Operating profit / loss	-193.2	-156.4
Cash flow from operating activities	-198.6	-179.6
Cash and short-term investments (June 30)	400.2	762.7

IMPORTANT INFORMATION

IN SWEDEN, THIS PRESS RELEASE IS DIRECTED ONLY AT PERSONS WHO ARE QUALIFIED INVESTORS.

MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV AND ZONDA PARTNERS AB ARE ACTING FOR HANSA BIOPHARMA AND FOR NO ONE ELSE IN CONNECTION WITH THE TRANSACTION AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN HANSA BIOPHARMA FOR PROVIDING THE PROTECTIONS AFFORDED TO CUSTOMERS OF MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV AND ZONDA PARTNERS AB OR FOR AFFORDING ADVICE IN RELATION TO THE TRANSACTION, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO IN THIS ANNOUNCEMENT. EITHER OF THE MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV AND ZONDA PARTNERS AB MAY PARTICIPATE IN THE TRANSACTION ON A PROPRIETARY BASIS.

SOLELY FOR THE PURPOSES OF THE PRODUCT GOVERNANCE REQUIREMENTS CONTAINED WITHIN: (A) EU DIRECTIVE 2014/65/EU ON MARKETS IN FINANCIAL INSTRUMENTS, AS AMENDED ("MIFID II"); (B) ARTICLES 9 AND 10 OF COMMISSION DELEGATED DIRECTIVE (EU) 2017/593 SUPPLEMENTING MIFID II; AND (C) LOCAL IMPLEMENTING MEASURES (TOGETHER, THE "MIFID II PRODUCT GOVERNANCE REQUIREMENTS"), AND DISCLAIMING ALL AND ANY LIABILITY, WHETHER ARISING IN TORT, CONTRACT OR OTHERWISE, WHICH ANY "MANUFACTURER" (FOR THE PURPOSES OF THE MIFID II PRODUCT GOVERNANCE REQUIREMENTS) MAY OTHERWISE HAVE WITH RESPECT THERETO, THE NEW SHARES IN THE PLACING (THE "ISSUE SHARES") HAVE BEEN SUBJECT TO A PRODUCT APPROVAL PROCESS, WHICH HAS DETERMINED THAT THE ISSUE SHARES ARE: (I) COMPATIBLE WITH AN END TARGET MARKET OF RETAIL INVESTORS AND INVESTORS WHO MEET THE CRITERIA OF PROFESSIONAL CLIENTS AND ELIGIBLE COUNTERPARTIES, EACH AS DEFINED IN MIFID II; AND (II) ELIGIBLE FOR DISTRIBUTION THROUGH ALL DISTRIBUTION CHANNELS AS ARE PERMITTED BY MIFID II (THE "TARGET MARKET ASSESSMENT"). NOTWITHSTANDING THE TARGET MARKET ASSESSMENT, DISTRIBUTORS SHOULD NOTE THAT: THE PRICE OF THE ISSUE SHARES MAY DECLINE AND INVESTORS COULD LOSE ALL OR PART OF THEIR INVESTMENT; THE ISSUE SHARES OFFER NO GUARANTEED INCOME AND NO CAPITAL PROTECTION; AND AN INVESTMENT IN THE ISSUE SHARES IS COMPATIBLE ONLY WITH INVESTORS WHO DO NOT NEED A GUARANTEED INCOME OR CAPITAL PROTECTION, WHO (EITHER ALONE OR IN CONJUNCTION WITH AN APPROPRIATE FINANCIAL OR OTHER ADVISER) ARE CAPABLE OF EVALUATING THE MERITS AND RISKS OF SUCH AN INVESTMENT AND WHO HAVE SUFFICIENT RESOURCES TO BE ABLE TO BEAR ANY LOSSES THAT MAY RESULT THEREFROM. THE TARGET MARKET ASSESSMENT IS WITHOUT PREJUDICE TO THE REQUIREMENTS OF ANY CONTRACTUAL, LEGAL OR REGULATORY SELLING RESTRICTIONS IN RELATION TO THE PLACING. FURTHERMORE, IT IS NOTED THAT, NOTWITHSTANDING THE TARGET MARKET ASSESSMENT, MORGAN STANLEY & CO. INTERNATIONAL PLC, VAN LANSCHOT KEMPEN WEALTH MANAGEMENT NV OR ZONDA PARTNERS AB WILL ONLY PROCURE INVESTORS WHO MEET THE CRITERIA OF PROFESSIONAL CLIENTS AND ELIGIBLE COUNTERPARTIES.

FOR THE AVOIDANCE OF DOUBT, THE TARGET MARKET ASSESSMENT DOES NOT CONSTITUTE: (A) AN ASSESSMENT OF SUITABILITY OR APPROPRIATENESS FOR THE PURPOSES OF MIFID II; OR (B) A RECOMMENDATION TO ANY INVESTOR OR GROUP OF INVESTORS TO INVEST IN, OR PURCHASE, OR TAKE ANY OTHER ACTION WHATSOEVER WITH RESPECT TO THE ISSUE SHARES.

EACH DISTRIBUTOR IS RESPONSIBLE FOR UNDERTAKING ITS OWN TARGET MARKET ASSESSMENT IN RESPECT OF THE ISSUE SHARES AND DETERMINING APPROPRIATE DISTRIBUTION CHANNELS.

THIS PRESS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS THAT REFLECT THE COMPANY'S INTENTIONS, BELIEFS, OR CURRENT EXPECTATIONS ABOUT AND TARGETS FOR THE COMPANY'S FUTURE RESULTS OF OPERATIONS, FINANCIAL CONDITION, LIQUIDITY, PERFORMANCE, PROSPECTS, ANTICIPATED GROWTH, STRATEGIES AND OPPORTUNITIES AND THE MARKETS IN WHICH THE COMPANY OPERATES. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL FACTS AND MAY BE IDENTIFIED BY WORDS SUCH AS "BELIEVE", "EXPECT", "ANTICIPATE", "INTEND", "MAY", "PLAN", "ESTIMATE", "WILL", "SHOULD", "COULD", "AIM" OR "MIGHT", OR, IN EACH CASE, THEIR NEGATIVE, OR SIMILAR EXPRESSIONS. THE FORWARD-LOOKING STATEMENTS IN THIS PRESS RELEASE ARE BASED UPON VARIOUS ASSUMPTIONS, MANY OF WHICH ARE BASED, IN TURN, UPON FURTHER ASSUMPTIONS. ALTHOUGH THE COMPANY BELIEVES THAT THE EXPECTATIONS REFLECTED IN THESE FORWARD-LOOKING STATEMENTS ARE REASONABLE, IT CAN GIVE NO ASSURANCES THAT THEY WILL MATERIALIZE OR PROVE TO BE CORRECT. BECAUSE THESE STATEMENTS ARE BASED ON ASSUMPTIONS OR ESTIMATES AND ARE SUBJECT TO RISKS AND UNCERTAINTIES, THE ACTUAL RESULTS OR OUTCOME COULD DIFFER MATERIALLY FROM THOSE SET OUT IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF MANY FACTORS. SUCH RISKS, UNCERTAINTIES, CONTINGENCIES AND OTHER IMPORTANT FACTORS COULD CAUSE ACTUAL EVENTS TO DIFFER MATERIALLY FROM THE EXPECTATIONS EXPRESSED OR IMPLIED IN THIS RELEASE BY SUCH FORWARD-LOOKING STATEMENTS. THE COMPANY DOES NOT GUARANTEE THAT THE ASSUMPTIONS UNDERLYING THE FORWARD-LOOKING STATEMENTS IN THIS PRESS RELEASE ARE FREE FROM ERRORS NOR DOES IT ACCEPT ANY RESPONSIBILITY FOR THE FUTURE ACCURACY OF THE OPINIONS EXPRESSED IN THIS PRESS RELEASE OR ANY OBLIGATION TO UPDATE OR REVISE THE STATEMENTS IN THIS PRESS RELEASE TO REFLECT SUBSEQUENT EVENTS. UNDUE RELIANCE SHOULD NOT BE PLACED ON THE FORWARD-LOOKING STATEMENTS IN THIS PRESS RELEASE. THE INFORMATION, OPINIONS AND FORWARD-LOOKING STATEMENTS CONTAINED IN THIS PRESS RELEASE SPEAK ONLY AS AT ITS DATE AND ARE SUBJECT TO CHANGE WITHOUT NOTICE. NEITHER THE COMPANY NOR ANYONE ELSE UNDERTAKE ANY OBLIGATION TO REVIEW, UPDATE, CONFIRM OR TO RELEASE PUBLICLY ANY REVISIONS TO ANY FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS THAT OCCUR OR CIRCUMSTANCES THAT ARISE IN RELATION TO THE CONTENT OF THIS PRESS RELEASE.